Latest Hotspot

FDA Approves Ubix Therapeutics' First Clinical Trial for Oral BTK Inhibitor UBX-303-1 to Treat Resistant B-Cell Cancers

8 January 2024
3 min read

Ubix Therapeutics, Inc., a biotech firm focused on creating groundbreaking cancer treatments through the mechanism of targeted protein degradation, has disclosed that the U.S. Food and Drug Administration has granted approval to commence with the firm’s exploratory new pharmaceutical submission for UBX-303-1. This oral degradation agent is designed for the management of recurrent or resistant B-cell malignancies.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Ubix is set to commence a preliminary phase 1 trial within the United States upon receiving authorization, with intention to branch out the research to testing locations across Europe and South Korea soon thereafter. This exploratory phase 1a/1b trial will be an open-label study, focusing on dose-escalation and expansion to ascertain the security, pharmacokinetic properties, and pharmacodynamic effects of UBX-303-1 on individuals suffering from recurring or resistant B-cell cancers. The inaugural dosing for a participant is projected for the earlier part of 2024.

UBX-303-1 is a novel, potentially superior small molecule degrader that selectively targets Bruton’s tyrosine kinase (BTK). BTK is instrumental in the pathway of B cell receptor signaling, which is essential for the proliferation and survival of cancer cells in B-cell malignancies, especially when signaling goes awry. Notably, close to 50% of patients receiving current BTK inhibitor treatments terminate their use due to severe side effects such as atrial fibrillation, hemorrhage, cardiac failure, and the evolution of drug-resistant mutations.

During preclinical tests, UBX-303-1 showed promising selectivity towards its target and potent inhibition of tumor proliferation in both cell culture and animal models. UBX-303-1 has also proven to be effective in dismantling BTK proteins in the presence of a spectrum of resistant mutations.

Ubix Therapeutics' Chief Executive Officer, BK Seo, remarked, “The green light for the Investigational New Drug (IND) application for UBX-303-1 marks a pivotal accomplishment for our enterprise and the Targeted Protein Degradation (TPD) sector. UBX-303-1 represents the inaugural TPD medication fashioned through our in-house Degraducer® technology and now moving towards clinical testing. We are optimistic that UBX-303-1 may introduce novel therapeutic paths for patients grappling with recurring or resistant B-cell cancers. As Ubix advances its TPD project line-up, our pledge to innovation is unwavering in our mission to deliver groundbreaking treatments to those in medical need.”

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of January 6, 2024, there are 172 investigational drugs for the BTK target, including 114 indications, 201 R&D institutions involved, with related clinical trials reaching 1281, and as many as 13089 patents.

UBX-303-1 is a PROTACs drug that targets BTK and has potential applications in the treatment of hematologic neoplasms. It is currently in the preclinical phase of development. Further research and clinical trials will be needed to determine the safety and efficacy of UBX-303-1 in treating hematologic neoplasms.

图形用户界面, 文本

描述已自动生成

What is Market Exclusivity in US?
"What" Series
2 min read
What is Market Exclusivity in US?
8 January 2024
Exclusivity refers to certain delays and prohibitions on approval of competitor drugs available under the statute that attach upon approval of a drug or of certain supplements.
Read →
NKGen Biotech, Inc. has begun treating the first participant in a Phase 1/2a Study with its SNK01 for moderate Alzheimer's Disease
Latest Hotspot
3 min read
NKGen Biotech, Inc. has begun treating the first participant in a Phase 1/2a Study with its SNK01 for moderate Alzheimer's Disease
5 January 2024
NKGen Biotech, Inc. declares the commencement of treatment in its initial participant within a Phase 1/2a Study using its own SNK01, aimed for moderate Alzheimer's Disease.
Read →
What are STING agonists and how do you quickly get the latest development progress?
What are STING agonists and how do you quickly get the latest development progress?
5 January 2024
STING agonists are drugs that activate the STING pathway, enhancing immune response against diseases like cancer.
Read →
NeuroBo Pharma files IND with FDA for Phase 1 trial of anti-obesity compound DA-1726
Latest Hotspot
3 min read
NeuroBo Pharma files IND with FDA for Phase 1 trial of anti-obesity compound DA-1726
5 January 2024
NeuroBo Pharma has filed an Investigational New Drug request with the FDA, seeking approval to commence a Phase 1 trial on compound DA-1726 aimed at combating obesity.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.